This weekend is the 15th annual World Conference on Lung Cancer, sponsored by tge International Assoc. for The Study Of Lung Cancer (IASLC). It takes place Sunday October 27th through Wednesday 30th (Site). Abstracts can be found here. In particular, we want to speak briefly about 7 presentations. PD1 inhibitors Bristol-Myers (BMY), Merck (MRK) and Roche (RHHBY) […]
September 12- EOD
Another relatively weak day in biotech land but this is not to say that the market in general was particularly strong. It is not surprising that both the market and biotechs seems to be taking a breather and would also not be surprising to see it last more than a few days. That being said, […]
September 12- EOD
Another relatively weak day in biotech land but this is not to say that the market in general was particularly strong. It is not surprising that both the market and biotechs seems to be taking a breather and would also not be surprising to see it last more than a few days. That being said, […]
September 12- EOD
Another relatively weak day in biotech land but this is not to say that the market in general was particularly strong. It is not surprising that both the market and biotechs seems to be taking a breather and would also not be surprising to see it last more than a few days. That being said, […]
INFI – Infinity Pharma, Staying The Course
This has been one heck of a roller-coaster ride. The stock took 8 months to triple in price, and just 2 to give it all back. Shares began to swoon prior to data presentations at ASCO and ICML. We had expected positive results to soothe the market, but this was not the case. Investors focused […]
Impressions from ASCO 2013 Days 3 and 4
Having survived ASCO 2013, we wanted to review some of the main data from Days 3 and 4. After a very long first 2 sessions, Day 3 and 4 were less data heavy, however, the outcomes from some of these had a dramatic effect for some (like CLVS, INFI, TSRO and SNTA). PD1’s belle of […]
Updates out of ESMO12
The European Society for Medical Oncology (ESMO) Congress 2012 kicked off this weekend and goes until October 2nd(Tuesday). Abstracts with data for those presentations that have already occurred can be viewed and searched here(link). We did get several updates from companies that we would like to review. First up is Threshold Pharmaceuticals (NASDAQ: THLD). On Saturday, they presented […]
ESMO12 Abstracts of interest
The European Society for Medical Oncology (ESMO) Congress 2012 kicks off on September 28th thru October 2nd. Abstract titles are currently able to be viewed and searched here(link), but no other descriptive information is available. Abstracts will be available before-hand on September 17th, with late-breaking abstracts coming during the Congress. Synta Pharmaceuticals (NASDAQ: SNTA) Several sources […]
A flurry of upcoming data before the end of June
With the close of the first half of 2012 upon us, we wanted to highlight some of those expected to report data or regulatory decisions before the end of June. Dynavax (NASDAQ: DVAX) is expected to report whether the FDA will designate priority review upon their Biologics License Application (BLA) for HEPLISAV. They are seeking […]
Updates from the Jefferies Global Healthcare Conference
The 2012 Jefferies Global Healthcare Conference was held June 4-7, 2012. You can access the full schedule and webcasts here. I’ll provide brief updates on the presentations by several companies in this post. Keep your eye on the Chimera Proprietary Calendar for all upcoming investor meetings, with links to the webcasts and schedules. Note that […]
Heat Shock Protein 90 (HSP90) inhibitors: Back in the spotlight – Part 1
Heat Shock Protein 90 (HSP90) was originally proposed as a cancer drug target in the 1990s, though no drug in this class have ever successfully completed a randomized clinical trial, let alone achieve regulatory approval. Despite repeated setbacks, HSP90 inhibitors are poised to find a significant niche in the evolving cancer treatment landscape. We will […]
Updates from the Roth Captial Partners Growth Conference
The annual Roth Capital Partners Growth Conference was held March 11-14, 2012. Find the complete presentation schedule and links to webcasts here. Isis Pharma (NASDAQ: ISIS) KYNAMRO (mipomersen) NDA will be filed in the next few weeks before end of quarter (missing this guidance would destroy the last shred of credibility ISIS management has […]
Updates from the Cowen & Co. Healthcare Conference
The early spring biotech investor conference calendar continued with the annual Cowen & Co. Healthcare Conference held March 5-7, 2012 in Boston, MA. As always, my webcast notes below contain only key updates, changes, or new information, and do not represent a complete reprise of any presentation. Additional details on many of these companies can […]
ASCO 2012: American Society of Clinical Oncology Preview Part 2
The 2012 American Society of Clinical Oncology (ASCO) Annual Meeting[link] will take place from June 1st to 5th in Chicago. This is the world’s largest meeting of oncology professionals where some of the industry’s most important data presentations will take place. With conferences like these, come the abstracts releases for presentations; this year abstracts will […]
Updates from the Citi Global Healthcare Conference
The annual Citi Global Healthcare Conference was held February 27-29, 2012, and as always we listened in on the webcasts to identify key takeaways for Chimera Research Group shareholders. These write-ups may be brief due to overlap with comments at other recent investor conferences – see links below. Amarin $AMRN (Leerink Swann notes – company overview) “We […]
Quick updates from BIO CEO & Investor Conference
The annual BIO CEO & Investor conference was held February 13-14th in New York, a key forum for small biotech companies, especially those that do not receive an invite to the JP Morgan conference in January. Below are some very quick notes from a number of presentations; be sure to note some changes in the […]
Biotech catalysts at two upcoming medical conferences
We want to take a moment to highlight two upcoming oncology focused medical conferences that will showcase data that represent potential catalysts for several biotech companies we’re tracking. First up, we have the 2012 ASCO Gastrointestinal Cancers Symposium from January 19-21, 2012. This conference will be focused on developments in the treatment of cancers of […]
